<p>Agenus Inc.（纳斯达克代码：AGEN - 免费报告）- HC Wainwright 在 2023 年 1 月 15 日（星期四）发布的研究报告中对 Agenus 的 2030 财年收益进行了预测。HC Wainwright 的分析师 E. Bodnar 预计该生物技术公司将在这一年每股收益为 0.34 美元。HC Wainwright 目前对该股票给予 “买入” 评级。市场普遍预计 Agenus 当前全年的每股收益为（-12.55 美元）。</p>
<p>另外，Weiss Ratings 在 2022 年 12 月 29 日（星期一）发布的报告中重申了对 Agenus 股票的 “卖出（e+）” 评级。两位分析师对该股票给予了买入评级，两位给予了持有评级，还有一位对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价为 14.50 美元。</p>
<p><strong>查看我们最新的 AGEN 股票分析</strong></p>
<h2>Agenus 股票下跌 9.2%</h2>
<p>纳斯达克：AGEN 周一开盘价为 3.34 美元。该公司的市值为 1.1359 亿美元，市盈率为-1.57，贝塔值为 1.58。该公司的 50 日移动平均线为 3.90 美元，200 日移动平均线为 4.42 美元。Agenus 的 52 周低点为 1.38 美元，52 周高点为 7.34 美元。</p>
<p>Agenus（纳斯达克：AGEN - 获取免费报告）最近于 2022 年 11 月 10 日发布了其收益结果。该生物技术公司报告季度每股收益（EPS）为 1.94 美元，低于市场共识预期的 2.63 美元，差距为 0.69 美元。该公司季度收入为 3024 万美元，而分析师预期为 8039 万美元。</p>
<h2>Agenus 的机构交易</h2>
<p>几家大型投资者最近增加或减少了对 AGEN 的持股。Invesco Ltd.在第一季度购买了 Agenus 的新头寸，价值约为 88,000 美元。AQR Capital Management LLC 在第一季度将其在 Agenus 的持股增加了 3080.3%。AQR Capital Management LLC 目前拥有 441,486 股该生物技术公司的股票，价值 664,000 美元，此前在上个季度又购买了 427,604 股。Acadian Asset Management LLC 在第一季度收购了 Agenus 的新股份，价值约为 58,000 美元。Strs Ohio 在第一季度购买了 Agenus 的新股份，价值约为 214,000 美元。最后，Wealth Enhancement Advisory Services LLC 在第二季度收购了 Agenus 的新头寸，价值约为 85,000 美元。目前 61.46% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Agenus</h2>
<p>（获取免费报告）</p>
<p>Agenus, Inc. 纳斯达克：AGEN 是一家临床阶段的免疫肿瘤学公司，总部位于马萨诸塞州列克星敦。该公司专注于发现和开发旨在调节免疫系统对癌症反应的疗法。Agenus 利用其在检查点调节、疫苗技术和佐剂系统方面的专有平台，旨在提供增强抗肿瘤活性的联合治疗方案，适用于多种实体肿瘤和血液恶性肿瘤。</p>
<p>Agenus 的产品线包括针对免疫检查点的单克隆抗体、基于细胞因子的治疗药物和基于其工程热休克蛋白（HSP）平台的疫苗候选者。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Agenus 更好</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防联储” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Agenus 吗？</h2>
<p>在考虑 Agenus 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买...而 Agenus 并不在名单上。</p>
<p>虽然 Agenus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

00847G804

<p>HC Wainwright 发布了对 Agenus Inc.（NASDAQ: AGEN）2030 财年的盈利预测，预计每股收益为 0.34 美元。该公司维持 “买入” 评级，而当前全年盈利的共识预期为每股（12.55）美元。Agenus 股票目前被评为 “持有”，目标价格为 14.50 美元。该股票已下跌 9.2%，开盘价为 3.34 美元，市值为 1.1359 亿美元。近期交易活动显示该公司获得了显著的机构投资，专注于免疫肿瘤治疗</p>

<p>Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn $0.34 per share for the year. HC Wainwright currently has a &#34;Buy&#34; rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share.</p>
<div class="lb-trans"><p>Agenus Inc.（纳斯达克代码：AGEN - 免费报告）- HC Wainwright 在 2023 年 1 月 15 日（星期四）发布的研究报告中对 Agenus 的 2030 财年收益进行了预测。HC Wainwright 的分析师 E. Bodnar 预计该生物技术公司将在这一年每股收益为 0.34 美元。HC Wainwright 目前对该股票给予 “买入” 评级。市场普遍预计 Agenus 当前全年的每股收益为（-12.55 美元）。</p>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Agenus in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus target price of $14.50.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 2022 年 12 月 29 日（星期一）发布的报告中重申了对 Agenus 股票的 “卖出（e+）” 评级。两位分析师对该股票给予了买入评级，两位给予了持有评级，还有一位对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价为 14.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AGEN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 AGEN 股票分析</strong></p>
</div><h2>Agenus Stock Down 9.2%</h2>
<div class="lb-trans"><h2>Agenus 股票下跌 9.2%</h2>
</div><p>NASDAQ:AGEN opened at $3.34 on Monday. The company has a market cap of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. The firm's 50 day moving average is $3.90 and its two-hundred day moving average is $4.42. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.</p>
<div class="lb-trans"><p>纳斯达克：AGEN 周一开盘价为 3.34 美元。该公司的市值为 1.1359 亿美元，市盈率为-1.57，贝塔值为 1.58。该公司的 50 日移动平均线为 3.90 美元，200 日移动平均线为 4.42 美元。Agenus 的 52 周低点为 1.38 美元，52 周高点为 7.34 美元。</p>
</div><p>Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The company had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million.</p>
<div class="lb-trans"><p>Agenus（纳斯达克：AGEN - 获取免费报告）最近于 2022 年 11 月 10 日发布了其收益结果。该生物技术公司报告季度每股收益（EPS）为 1.94 美元，低于市场共识预期的 2.63 美元，差距为 0.69 美元。该公司季度收入为 3024 万美元，而分析师预期为 8039 万美元。</p>
</div><h2>Institutional Trading of Agenus</h2>
<div class="lb-trans"><h2>Agenus 的机构交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in AGEN. Invesco Ltd. purchased a new position in Agenus in the first quarter valued at about $88,000. AQR Capital Management LLC grew its stake in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Agenus in the first quarter valued at about $58,000. Strs Ohio purchased a new stake in shares of Agenus during the 1st quarter valued at about $214,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Agenus during the 2nd quarter worth approximately $85,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 AGEN 的持股。Invesco Ltd.在第一季度购买了 Agenus 的新头寸，价值约为 88,000 美元。AQR Capital Management LLC 在第一季度将其在 Agenus 的持股增加了 3080.3%。AQR Capital Management LLC 目前拥有 441,486 股该生物技术公司的股票，价值 664,000 美元，此前在上个季度又购买了 427,604 股。Acadian Asset Management LLC 在第一季度收购了 Agenus 的新股份，价值约为 58,000 美元。Strs Ohio 在第一季度购买了 Agenus 的新股份，价值约为 214,000 美元。最后，Wealth Enhancement Advisory Services LLC 在第二季度收购了 Agenus 的新头寸，价值约为 85,000 美元。目前 61.46% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Agenus</h2>
<div class="lb-trans"><h2>关于 Agenus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>Agenus, Inc. 纳斯达克：AGEN 是一家临床阶段的免疫肿瘤学公司，总部位于马萨诸塞州列克星敦。该公司专注于发现和开发旨在调节免疫系统对癌症反应的疗法。Agenus 利用其在检查点调节、疫苗技术和佐剂系统方面的专有平台，旨在提供增强抗肿瘤活性的联合治疗方案，适用于多种实体肿瘤和血液恶性肿瘤。</p>
</div><p>Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.</p>
<div class="lb-trans"><p>Agenus 的产品线包括针对免疫检查点的单克隆抗体、基于细胞因子的治疗药物和基于其工程热休克蛋白（HSP）平台的疫苗候选者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Agenus</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Agenus 更好</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防联储” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AGEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agenus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Agenus 吗？</h2>
</div><p>Before you consider Agenus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Agenus 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买...而 Agenus 并不在名单上。</p>
</div><p>While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Agenus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 发布了 Agenus 公司 2030 财年的收益预估